Sebia USA’s Post

Continuing on with #vasculitisawareness... today we will learn about GPA, one of three ANCA vasculitis (ANCA = Antineutrophilic cytoplasmic antibody). Help raise awareness about #vasculitis and repost! #raredisease #VAM2024

New Study shows effect of prophylactic ranibizumab (PR) on drusen volume, macular layer thicknesses, and progression of GA. Read all about it > https://bit.ly/47R2Iyb #prophylacticranibizumab

Continuing on with #vasculitisawareness... today we will learn about GPA, one of three ANCA vasculitis (ANCA = Antineutrophilic cytoplasmic antibody). Help raise awareness about #vasculitis and repost! #raredisease #VAM2024

New Study shows effect of prophylactic ranibizumab (PR) on drusen volume, macular layer thicknesses, and progression of GA. 📰 Read on to learn more https://bit.ly/46xeU6b #prophylacticranibizumab

New Study shows effect of prophylactic ranibizumab (PR) on drusen volume, macular layer thicknesses, and progression of GA. 📰 Read on to learn more https://bit.ly/46xeU6b #prophylacticranibizumab

Meet Hery at Advanced therapies congress and discuss about protein characterization and quantification!!

Very exciting news for our ATTR-CM patients! Alnylam just announced their positive topline results from the HELIOS-B Phase 3 study of Vutrisiran! 📊 Key Highlights: - Statistically significant results on all primary and secondary endpoints - 28% reduction in composite all-cause mortality and recurrent cardiovascular events (overall population) - 33% reduction in composite all-cause mortality and recurrent cardiovascular events (monotherapy population) - Significant improvements in disease progression measures: 6-minute walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA class - Consistent benefits across all key subgroups, including those on baseline tafamidis - Encouraging safety profile So thrilled about these findings and their potential impact on patient care. Stay tuned for more updates! #Healthcare #Biotech #ClinicalResearch #Vutrisiran #Alnylam #RNAi

Do #durvalumab and #bevacizumab added to TACE make an effective combination for patients with unresectable #hepatocellularcarcinoma? See what was found in the EMERALD-1 study that was presented at #GI24:

Join experts at #AASLD as they share data on emerging targeted Primary biliary #cholangitis treatments.

We are excited to share findings on cervical intraepithelial neoplasia (CIN) and its correlation with Paraoxonase 1 (PON1) activity. The study delves into the intricate world of enzyme dynamics in combating carcinogenic radicals from lipids. Drazan Butorac, Ivana Celap, Sanja Kackov, Tomislav Miletić, Andrea Hulita, Petra Turčić, Dubravka Rašić, Ivana Stojanović, and Marija Grdić Rajković analyzed 65 CIN patients alongside 109 healthy counterparts, evaluating lipid parameters, tiols, reduced glutathione (GSH), and PON1 activity and malondialdehyde (MDA) using various technics. Noteworthy disparities highlighted the significance of reduced PON1 arylesterase activity and altered MDA and GSH concentrations in CIN patients. These insights contribute to understanding the complex interplay between enzyme activity and cervical neoplasia. 🌟 Read the full article: https://lnkd.in/g7CzwwWt #medicalresearch #enzymes #scientificjournal #oxidativestress #cervicalhealth 🧬